Credit and interest ratespositive · 4 filings
“Interest expense was $2.7 million in the first three months of 2026, reflecting a decrease of $0.2 million from the first three months of 2025, as a result of a lower interest rate.”10-Q · May 5, 2026 ↗
CNTA
CNTA
Market read
CNTA's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 39 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
Company+0.1% todayVolume comparison unavailable
Market group0 of 39 activeBiotechnology Innovations · unavailable
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- Company entered into a Transaction Agreement with Eli Lilly; the acquisition is expected to close in Q3 2026 subject to customary closing conditions, including regulatory and shareholder approvals.
Invalidation: The isolated read changes if CNTA's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 39 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- Company entered into a Transaction Agreement with Eli Lilly; the acquisition is expected to close in Q3 2026 subject to customary closing conditions, including regulatory and shareholder approvals.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods4
Price observations276
Usable filing statements112
Verified relationships3
Evidence supporting the case
- Credit and interest rates has repeated favorable evidence across 4 filings.
Evidence challenging the case
- Diluted shares increased 18.6% in the latest annual period.
- Product pipeline and R&D has repeated adverse evidence across 4 filings.
Questions before a position
- EV/sales is 12782% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Jun 29, 2026
40.506m+57.7%12m+210.6%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2022-12-31$0—$-2.31—
2023-12-31$6.9M—$-1.57+3.0%
2024-12-31$0-100.0%$-2.06+19.0%
2025-12-31$15.0M—$-1.46+18.6%
What management says matters
Persistent and emerging business drivers
Legal and regulatory exposuremixed · 4 filings
“We expect research and development expenses to increase significantly over the next several years due to increases in costs to conduct clinical trials for current product candidates and other clinical trials for future product candidates and costs to prepare…”10-Q · May 5, 2026 ↗
Product pipeline and R&Dnegative · 4 filings
“We expect research and development expenses to increase significantly over the next several years due to increases in costs to conduct clinical trials for current product candidates and other clinical trials for future product candidates and costs to prepare…”10-Q · May 5, 2026 ↗
Foreign exchangenegative · 1 filings
“Other Non-Operating Income (Expense), net Other non-operating income (expense), net for the three months ended March 31, 2026 was a loss of $1.0 million, compared to a gain of $1.0 million three months ended March 31, 2025, with the change resulting from fore…”10-Q · May 5, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 366.4× · EV/sales 369.7×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
How the market is pricing the story
40.56+0.1% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 23 Jun, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for CNTA. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for CNTA. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind CNTA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
GMABGenmab A/SpartnerNov 5, 2025 ▾
“Genmab License Agreement Background On February 14, 2025, the Company entered into a license agreement (the “License Agreement”) with Genmab A/S (“Genmab”) pursuant to which the Company granted to Genmab an exclusive worldwide license to leverage its propriet…”
LLYEli Lilly and CompanypartnerMay 5, 2026 ▾
“On March 31, 2026, the Company entered into a Transaction Agreement and plan of merger with Eli Lilly (the “Transaction Agreement”), pursuant to which the Company will be acquired in a transaction expected to close in the third quarter of 2026, subject to the…”
Depended on by
HRMYHarmony Biosciences Holdings, Inc.competitorFeb 24, 2026 ▾
“Other potential future competitive products are currently in development, including Axsome Therapeutics’ AXS-12 (reboxetine) product candidate, Suven Life Sciences’ SUVN-G3031 H3 inverse agonist product candidate, NLS Pharmaceutics mazindol ER product candida…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CNTA is currently a Follower in the organic co-movement group Biotechnology Innovations. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for CNTA; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.